Alkermes Inc. plc (ALKS)
Alkermes Inc. plc (ALKS) is a biopharmaceutical company that specializes in developing innovative medicines for central nervous system (CNS) disorders, addiction, and oncology. The company focuses on utilizing advanced drug delivery technology to improve the effectiveness and convenience of its therapies. Alkermes has a history of developing both proprietary and partnered treatments, with an emphasis on integrating science and technology to address complex medical conditions.
Company News
Alkermes (NASDAQ:ALKS) was analyzed by 6 analysts in the last quarter, with a range of viewpoints from bullish to bearish. The analysts provided an average 12-month price target of $36.33, with a high of $48.00 and a low of $31.00. The article also provides financial insights into Alkermes, including its market capitalization, revenue growth, net margin, and debt management.
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Investors should consider this list of healthcare stocks for 2024
The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors.
